The U.S. Food and Drug Administration (FDA) granted a supplemental efficacy approval for Epcoritamab (brand name Epkinly) on November 18, 2025. This approval was for a supplemental application, BLA 761324 S-9, submitted by Genmab US, Inc., specifically focusing on the drug's efficacy.
Background
Epcoritamab, known by its brand name Epkinly, is a therapeutic agent developed by Genmab US, Inc. Supplemental applications, such as this BLA 761324 S-9, are submitted to the FDA to propose changes to an already approved product. These changes can include new indications, new dosing regimens, new manufacturing processes, or, as in this case, additional efficacy data that supports an expansion or modification of the drug's approved uses. This specific supplemental approval further establishes the drug's efficacy profile.
What this means
The FDA's decision to grant a supplemental efficacy approval for Epcoritamab indicates that the agency has reviewed and accepted new clinical or scientific data demonstrating the drug's effectiveness for an expanded or modified use. While the precise details of this specific expansion are not publicly detailed in the approval summary, such actions are crucial for broadening patient access to effective treatments. This type of approval can lead to the drug being prescribed for new patient populations, different stages of a disease, or under revised treatment protocols, ultimately enhancing its utility in clinical practice and reinforcing confidence in its therapeutic benefits. Clinicians and patients can anticipate potential updates to the drug's prescribing information reflecting this new efficacy data.
Source
The information regarding this supplemental efficacy approval was sourced from the U.S. Food and Drug Administration (FDA). The approval, identified as BLA 761324 S-9, was granted on November 18, 2025, and is publicly accessible on accessdata.fda.gov.